Cardiac Program, Peter Munk Cardiac Centre at Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada.
Cardiac Program, Peter Munk Cardiac Centre at Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada.
J Thorac Cardiovasc Surg. 2014 Jan;147(1):85-93. doi: 10.1016/j.jtcvs.2013.08.007. Epub 2013 Sep 29.
Our study examines the outcomes of the Ross procedure in a cohort of 212 patients prospectively followed with clinical and echocardiographic assessments.
Patients' mean age was 34 ± 9 years; 66% were men and 82% had congenital aortic valve disease. The median follow-up was 13.8 years. Patients who had reoperations continued to be followed and entered into the survival analysis.
There was 1 operative death as well as 9 late deaths (3 in patients who no longer had the Ross). Survival at 20 years was 93.6% and similar to the general population matched for age and sex. Fifteen patients required reoperations on the pulmonary autograft (4 repairs and 11 replacements), 8 on the pulmonary homograft, and 4 other cardiac procedures. At 20 years the freedom from reoperation on the pulmonary autograft was 81.8% and on the pulmonary homograft was 92.7%, and in both was 79.9%. Preoperative aortic insufficiency, aortic annulus diameter ≥15 mm/m(2), and being a man were associated with increased risk of reoperation on the pulmonary autograft. Twenty-six patients developed aortic insufficiency greater than mild and 25 patients developed pulmonary homograft dysfunction (defined as moderate or severe insufficiency and/or peak systolic gradient of >40 mm Hg). At 20 years the freedom from aortic insufficiency was 62.6% and freedom from pulmonary valve dysfunction was 53.5%.
Survival after the Ross procedure in this cohort was similar to the general population. Dilated aortic annulus and aortic insufficiency were associated with increased risk of developing aortic insufficiency. Pulmonary homograft dysfunction was common at 20 years.
我们的研究对 212 例前瞻性临床和超声心动图评估的罗斯手术患者的结果进行了检查。
患者平均年龄为 34±9 岁;66%为男性,82%患有先天性主动脉瓣疾病。中位随访时间为 13.8 年。接受再次手术的患者继续接受随访并纳入生存分析。
有 1 例手术死亡和 9 例晚期死亡(3 例在不再使用罗斯的患者中)。20 年生存率为 93.6%,与年龄和性别匹配的普通人群相似。15 例患者需要对肺动脉移植物进行再次手术(4 例修复和 11 例置换),8 例对肺动脉同种移植物进行再次手术,4 例进行其他心脏手术。20 年时,肺动脉移植物免于再次手术的比例为 81.8%,肺动脉同种移植物为 92.7%,两者均为 79.9%。术前主动脉瓣关闭不全、主动脉瓣环直径≥15mm/m2 和男性与肺动脉移植物再次手术风险增加相关。26 例患者出现中度以上主动脉瓣关闭不全,25 例患者出现肺动脉同种移植物功能障碍(定义为中度或重度关闭不全和/或收缩期峰值梯度>40mmHg)。20 年时,主动脉瓣关闭不全的无进展率为 62.6%,肺动脉瓣功能障碍的无进展率为 53.5%。
本队列中罗斯手术的生存率与普通人群相似。扩张的主动脉瓣环和主动脉瓣关闭不全与发生主动脉瓣关闭不全的风险增加相关。肺动脉同种移植物功能障碍在 20 年时很常见。